All In Biotech

Drug Trial Radar · NCT07389278

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

97

Planned (sponsor's estimate)

Start

Jun 1, 2027

Primary completion

Jun 30, 2032

Study completion Jun 30, 2035

Sponsor

Lead sponsor
Sabine Mueller, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).

Conditions

  • Glioblastoma
  • High-Grade Glioma (WHO III-IV)
  • High-grade Glioma
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Diffuse Hemispheric Glioma, H3G34 Mutant

Interventions

  • ADI-PEG 20 (Arginine deiminase pegylated)Drug

    Given intramuscularly (IM)

  • Temozolomide (TMZ)Drug

    Given orally (PO)

  • Standard of Care Radiation Therapy (RT)Radiation

    Undergo RT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with Treatment-emergent Adverse Events (TrAE) (Phase 1)Time frame: Up to 104 weeks
  2. Progression-Free Survival (PFS) for HGG histone-WT (Phase 2, Cohort 1)Time frame: Up to 12 months
  3. Progression-Free Survival (PFS) for H3K27 altered diffuse midline glioma (DMG) (Phase 2, Cohort 2)Time frame: Up to 12 months
  4. Progression-Free Survival (PFS) for H3G34 mutant diffuse hemispheric glioma (DHG) (Phase 2, Cohort 3)Time frame: Up to 10 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.